Abstract
4/2023
vol. 15
Case report
TACE combined with portal particle implantation in a case of stage IIIa primary hepatocellular carcinoma treated with sequential anlotinib
- Interventional Ward of Oncology Department, Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi, China
- Department of Gastroenterology, Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi, China
- Chemotherapy Ward, Cancer Department, Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi, China
- Academic Affairs Office of Youjiang Medical College for Nationalities, Baise, Guangxi, China
J Contemp Brachytherapy 2023; 15, 4: 283–289
Online publish date: 2023/08/31
Few cases of patients with Cheng’s type III portal vein tumor thrombus (PVTT) have been reported to achieve radical cure without recurrence over time. In this study, we reported on a 55-year-old male patient with a diagnosis of stage IIIa China liver cancer staging (CNLC), PVTT Cheng’s type III, mild cirrhosis, and chronic viral hepatitis B. TACE combined with radioactive iodine-125 (125I) particle implantation was applied to achieve radical treatment with sequential oral anlotinib hydrochloride capsules. This case might serve as a reference for the treatment of this disease.
Keywords
primary liver cancer, stage IIIa CNLC, trans-catheter arterial chemo-embolization, 125I
Indexed in
Integrated with
Editorial Policies
